Intercept Increases Chance Of Success In NASH Without Significant Delay

10 Feb 2017

Ocaliva could now qualify for accelerated approval in NASH by meeting either of two Phase III co-primary endpoints, whereas the trial initially was designed for success on both measures.

Intercept Pharmaceuticals Inc. is making a pair of protocol changes to the pivotal trial of its Ocaliva (obeticholic acid or OCA) in non-alcoholic steatohepatitis (NASH), but it maintains those will increase the odds of producing successful data, without pushing back the timelines in any material way.

Despite the protocol changes announced Feb. 10, Intercept said it should complete enrolling sufficient patients (about 750) by mid-2017 for an interim efficacy evaluation, likely in 2019, that could lead...

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

26 May 2025

• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.